Exact Sciences (EXAS) Stock Price, News & Analysis

Company Overview

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Key Stats

• Today's Range: $46.88 to $47.76
• 50-Day Range: $40.91 to $55.31
• 52-Week Range: $38.81 to $72.83
• Volume: 1.28 million shs
• Average Volume: 2.77 million shs
• Market Capitalization: $8.93 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $67.05
• Consensus Rating: Moderate Buy

Exact Sciences Stock Analysis - MarketRank™

Exact Sciences scored higher than 99% of companies evaluated by MarketBeat, and ranked 25th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Exact Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 19 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Exact Sciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Exact Sciences are expected to grow in the coming year, from ($0.58) to $0.50 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Exact Sciences is -8.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Exact Sciences is -8.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Exact Sciences has a PEG Ratio of 4.72. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Exact Sciences has a P/B Ratio of 3.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.68% of the float of Exact Sciences has been sold short.

Short Interest Ratio / Days to Cover

Exact Sciences has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Exact Sciences has recently decreased by 7.90%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Exact Sciences does not currently pay a dividend.

Dividend Growth

Exact Sciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.83

Percentage of Shares Shorted

3.68% of the float of Exact Sciences has been sold short.

Short Interest Ratio / Days to Cover

Exact Sciences has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Exact Sciences has recently decreased by 7.90%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 4.1 / 5
• News Sentiment: 1.36

News Sentiment

Exact Sciences has a news sentiment score of 1.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 18 news articles for Exact Sciences this week, compared to 12 articles on an average week.

Search Interest

18 people have searched for EXAS on MarketBeat in the last 30 days. This is an increase of 260% compared to the previous 30 days.

MarketBeat Follows

9 people have added Exact Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Exact Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $233,012.00 in company stock.

Percentage Held by Insiders

Only 1.20% of the stock of Exact Sciences is held by insiders.

Percentage Held by Institutions

88.82% of the stock of Exact Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

EXAS Stock Analysis - Frequently Asked Questions

How have EXAS shares performed this year?

Exact Sciences' stock was trading at $56.19 on January 1st, 2025. Since then, EXAS stock has decreased by 15.7% and is now trading at $47.3420.

How were Exact Sciences' earnings last quarter?

Exact Sciences Corporation (NASDAQ:EXAS) announced its quarterly earnings results on Wednesday, August, 6th. The medical research company reported $0.22 earnings per share for the quarter, topping analysts' consensus estimates of ($0.02) by $0.24. The company's quarterly revenue was up 16.0% on a year-over-year basis.
Read the conference call transcript.

Does Exact Sciences have any subsidiaries?

Exact Sciences subsidiaries include Ashion Analytics, Thrive Earlier Detection Corporation, Base Genomics Limited, Paradigm Diagnostics Inc., Viomics Inc., Biomatrica Inc., Armune BioScience, and more.

Who are Exact Sciences' major shareholders?

Top institutional investors of Exact Sciences include Geode Capital Management LLC (1.72%), Massachusetts Financial Services Co. MA (1.57%), Mackenzie Financial Corp (1.51%) and Champlain Investment Partners LLC (1.34%). Insiders that own company stock include Kevin T Conroy, Katherine S Zanotti, Sarah Condella, James Edward Doyle, Everett Cunningham, D Scott Coward, Daniel J Levangie, Jacob A Orville, Brian Baranick, Jeffrey Thomas Elliott and James Herriott.
View institutional ownership trends.

How do I buy shares of Exact Sciences?

Shares of EXAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Exact Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Exact Sciences investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Adobe (ADBE) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 8/06/2025
• Today: 8/28/2025
• Next Earnings (Estimated): 11/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:EXAS
• CIK: 1124140
• Web: www.exactsciences.com
• Phone: (608) 284-5700
• Fax: 608-284-5701
• Employees: 7,000
• Year Founded: 1995

Price Target and Rating

• Average Price Target for Exact Sciences: $67.05
• High Price Target: $90.00
• Low Price Target: $46.00
• Potential Upside/Downside: +43.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.91
• Research Coverage: 23 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.43)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: 4.72
• Net Income: -$1.03 billion
• Net Margins: -34.19%
• Pretax Margin: -34.51%
• Return on Equity: -1.75%
• Return on Assets: -0.76%

Debt

• Debt-to-Equity Ratio: 0.94
• Current Ratio: 2.89
• Quick Ratio: 2.56

Sales & Book Value

• Annual Sales: $2.76 billion
• Price / Sales: 3.21
• Cash Flow: $5.70 per share
• Price / Cash Flow: 8.19
• Book Value: $13.04 per share
• Price / Book: 3.58

Miscellaneous

• Outstanding Shares: 189,320,000
• Free Float: 187,047,000
• Market Cap: $8.84 billion
• Optionable: Optionable
• Beta: 0.93